Sanjay Asthana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11559003/publications.pdf

Version: 2024-02-01

277 papers	15,754 citations	20759 60 h-index	21474 114 g-index
346 all docs	346 docs citations	346 times ranked	19428 citing authors

#	Article	IF	Citations
1	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. Alzheimer's and Dementia, 2022, 18, 65-76.	0.4	18
2	Age-related differences in white matter microstructure measured by advanced diffusion MRI in healthy older adults at risk for Alzheimerâ€™s disease. Aging Brain, 2022, 2, 100030.	0.7	10
3	Crosswalk study on blood collectionâ€tube types for Alzheimer's disease biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12266.	1.2	8
4	Dissection of the polygenic architecture of neuronal AÎ² production using a large sample of individual iPSC lines derived from Alzheimerâ€™s disease patients. Nature Aging, 2022, 2, 125-139.	5.3	7
5	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1495.	5.8	11
6	The Wisconsin Alzheimer's Institute Dementia Diagnostic Clinic Network: A community of practice to improve dementia care. Journal of the American Geriatrics Society, 2022, 70, 2121-2133.	1.3	4
7	In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimerâ€™s Disease (AD) Patients. ACS Chemical Biology, 2022, 17, 3059-3068.	1.6	9
8	Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	1.6	12
9	Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers. Neurobiology of Aging, 2022, 117, 12-23.	1.5	7
10	Racial Differences in Associations of Cognitive Health Status With Happiness, Helplessness, and Hopelessness Among Older Adults: An Exploratory Study. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	0
11	Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to Î²-amyloid positivity. Sleep, 2022, 45, .	0.6	22
12	Cardiorespiratory fitness and cognition in persons at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	2
13	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	5.3	11
14	Latent Factor Structure and Measurement Invariance of the NIH Toolbox Cognition Battery in an Alzheimerâ€™s Disease Research Sample. Journal of the International Neuropsychological Society, 2021, 27, 412-425.	1.2	13
15	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimer's and Dementia, 2021, 17, 431-445.	0.4	80
16	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
17	In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease. Molecular and Cellular Proteomics, 2021, 20, 100081.	2.5	48
18	Measurement batch differences and betweenâ€batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12194.	1.2	2

#	Article	IF	Citations
19	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. Communications Biology, 2021, 4, 63.	2.0	28
20	Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. Journal of Alzheimer's Disease, 2021, 79, 1297-1305.	1.2	14
21	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. Neurology, 2021, 96, e2500-e2512.	1.5	32
22	Cigarette Smoking Status, Cigarette Exposure, and Duration of Abstinence Predicting Incident Dementia and Death: A Multistate Model Approach. Journal of Alzheimer's Disease, 2021, 80, 1013-1023.	1.2	13
23	Assessing Dementia Prevalence in the Wisconsin Longitudinal Study: Cohort Profile, Protocol, and Preliminary Findings. Journal of Alzheimer's Disease, 2021, 81, 751-768.	1.2	3
24	Impact of sex andAPOEÎµ4 on age-related cerebral perfusion trajectories in cognitively asymptomatic middle-aged and older adults: A longitudinal study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3016-3027.	2.4	33
25	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. Neurobiology of Aging, 2021, 102, 151-160.	1.5	6
26	Effects of simvastatin on white matter integrity in healthy middleâ€aged adults. Annals of Clinical and Translational Neurology, 2021, 8, 1656-1667.	1.7	10
27	Does Rural Living in Early Life Increase the Risk for Reduced Cognitive Functioning in Later Life?. Journal of Alzheimer's Disease, 2021, 82, 1171-1182.	1.2	9
28	The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults. Neurobiology of Aging, 2021, 105, 174-185.	1.5	1
29	Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in nonâ€demented adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12220.	1.2	3
30	CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12167.	1.2	2
31	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	2.8	19
32	Relationship of insulin resistance and glucose to tau PET positivity. Alzheimer's and Dementia, 2021, 17, .	0.4	0
33	CSF metabolites associated with CSF NeuroToolKit biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	1
34	CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	1
35	Relationships between wellâ€being and cognitive function among Native American, Black, and White participants in the Wisconsin Alzheimer's Disease Research Center. Alzheimer's and Dementia, 2021, 17, .	0.4	1
36	Greater COVIDâ€19 impact for underrepresented racial and ethnic minority groups: A survey study on the Wisconsin Alzheimerâ€™s Disease Research Center participants. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
37	Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	2
38	Age of amyloid onset, but not amyloid accumulation rate, differs across APOEâ€e4 carriers vs. nonâ€carriers in three cohorts and three methods. Alzheimer's and Dementia, 2021, 17, .	0.4	0
39	Increased adiposity is related to reduced neurite complexity in the hippocampus, fornix, and uncinate fasciculus of cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	1
40	Amyloid status is associated with deficits in connected speech language. Alzheimer's and Dementia, 2021, 17, .	0.4	0
41	The Interaction between Ventricle to Brain Ratio and Serum Klotho on Cognition in Older Adults at Risk for Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2021, 17, e058632.	0.4	1
42	CSF sphingomyelin metabolites in Alzheimerâ€™s disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, .	0.4	4
43	Diet and APOE as moderators of the relationship between trimethylamine Nâ€oxide and biomarkers of Alzheimer's disease and glial activation. Alzheimer's and Dementia, 2021, 17, e051827.	0.4	2
44	Areaâ€level deprivation is associated with rate of memory decline in late life within a communityâ€based cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
45	Fitness, independent of physical activity is associated with cerebral blood flow in adults at risk for Alzheimerâ€™s disease. Brain Imaging and Behavior, 2020, 14, 1154-1163.	1.1	27
46	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain, 2020, 143, 320-335.	3.7	100
47	Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume. JAMA Neurology, 2020, 77, 451.	4.5	80
48	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	4.4	33
49	MKâ€6240 imaging features, cognitive associations in preclinical Alzheimerâ€™s disease and a case with imagingâ€toâ€postmortem correlates. Alzheimer's and Dementia, 2020, 16, e043217.	0.4	1
50	Simvastatin maintains white matter integrity in healthy middleâ€aged adults with increased risk for Alzheimerâ€™s disease: A secondary analysis of a randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e043408.	0.4	0
51	The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043979.	0.4	0
52	Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065.	0.4	1
53	Bloodâ€brain barrier permeability measured by 7Î±â€hydroxyâ€3â€oxoâ€4â€cholestenoic acid in CSF associates with Alzheimerâ€™s pathology biomarkers in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e046582.	0.4	0
54	Association of Cardiovascular Risk Factors with Cerebral Perfusion in Whites and African Americans. Journal of Alzheimer's Disease, 2020, 75, 649-660.	1.2	11

#	Article	IF	Citations
55	Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12007.	1.2	43
56	Cortical Microstructural Alterations in Mild Cognitive Impairment and Alzheimerâ€™s Disease Dementia. Cerebral Cortex, 2020, 30, 2948-2960.	1.6	61
57	Neighborhood disadvantage is associated with accelerated cortical thinning and cognitive decline in cognitively unimpaired adults. Alzheimer's and Dementia, 2020, 16, .	0.4	2
58	Chronicity of amyloid: Methods for estimating amyloid onset and clinical research applications. Alzheimer's and Dementia, 2020, 16, e039782.	0.4	0
59	Cardiorespiratory Fitness Associates with Cerebral Vessel Pulsatility in a Cohort Enriched with Risk for Alzheimerâ€™s Disease. Brain Plasticity, 2020, 5, 175-184.	1.9	3
60	Factors Associated with Lumbar Puncture Participation in Alzheimerâ€™s Disease Research. Journal of Alzheimer's Disease, 2020, 77, 1559-1567.	1.2	19
61	Elevated Insulin and Insulin Resistance are Associated with Altered Myelin in Cognitively Unimpaired Middleâ€Aged Adults. Obesity, 2019, 27, 1464-1471.	1.5	19
62	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. NeuroImage: Clinical, 2019, 23, 101895.	1.4	28
63	Predicting Risk for Dementia: Is It Ready for the Clinic?. American Journal of Psychiatry, 2019, 176, 501-502.	4.0	3
64	Effects of Simvastatin on Augmentation Index Are Transient: Outcomes From a Randomized Controlled Trial. Journal of the American Heart Association, 2019, 8, e009792.	1.6	11
65	Association of Cardiovascular and Alzheimerâ€™s Disease Risk Factors with Intracranial Arterial Blood Flow in Whites and African Americans. Journal of Alzheimer's Disease, 2019, 72, 919-929.	1.2	14
66	Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center. Alzheimer's and Dementia, 2019, 15, 1533-1545.	0.4	64
67	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 129-138.	1.8	22
68	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology, 2019, 92, e1567-e1579.	1.5	73
69	KLOTHO heterozygosity attenuates APOE4 -related amyloid burden in preclinical AD. Neurology, 2019, 92, e1878-e1889.	1.5	40
70	Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. Journal of Alzheimer's Disease, 2019, 69, 111-121.	1.2	8
71	Measuring longitudinal cognition: Individual tests versus composites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 74-84.	1.2	69
72	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962

#	Article	IF	Citations
73	ICâ€Pâ€103: RELATIONSHIPS BETWEEN Pâ€TAU AND CHANGES IN MYELIN CONTENT AND COGNITIVE PERFORMANCE. Alzheimer's and Dementia, 2019, 15, P89.	0.4	0
74	P4â€637: EXAMINING THE ROLE OF CIGARETTE SMOKING AND CESSATION ON COMBINED RISK OF INCIDENT DEMENTIA, NURSING HOME PLACEMENT, AND DEATH IN COGNITIVELY HEALTHY AND MILD COGNITIVELY IMPAIRED ADULTS. Alzheimer's and Dementia, 2019, 15, P1571.	0.4	0
75	ICâ€Pâ€109: LOWER ARTERIAL BLOOD FLOW AND HIGHER PULSATILITY INDEX ARE ASSOCIATED WITH NEURONAL INJURY. Alzheimer's and Dementia, 2019, 15, P93.	0.4	0
76	ICâ€Pâ€149: DECREASED CORTICAL NEURITE DENSITY AND ORIENTATION DISPERSION IN ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2019, 15, P120.	0.4	0
77	P4â€623: LESSONS FROM A RESEARCH COLLABORATION WITH THE ONEIDA NATION OF WISCONSIN. Alzheimer's and Dementia, 2019, 15, P1565.	0.4	1
78	ICâ€Pâ€081: CSF MARKERS OF NEURODEGENERATION ARE ASSOCIATED WITH QUANTITATIVE T1. Alzheimer's and Dementia, 2019, 15, P72.	0.4	0
79	Neuropsychiatric symptoms in dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 437-454.	1.0	40
80	The evolution of geriatric neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 575-584.	1.0	0
81	P4â€583: MICROSTRUCTURAL ALTERATIONS WITH OLDER AGE EVALUATED USING THE NODDI MODEL IN A LARGE GROUP OF COGNITIVELY UNIMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P1544.	0.4	0
82	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	0.8	97
83	Hypertension and obesity moderate the relationship between Î²â€amyloid and cognitive decline in midlife. Alzheimer's and Dementia, 2019, 15, 418-428.	0.4	38
84	Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. NeuroImage: Clinical, 2019, 21, 101586.	1.4	24
85	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimerâ€™s disease in late-middle-aged adults. Brain Imaging and Behavior, 2019, 13, 41-52.	1.1	32
86	Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 188-195.	1.2	51
87	Age-accelerated cognitive decline in asymptomatic adults with CSF Î²-amyloid. Neurology, 2018, 90, e1306-e1315.	1.5	42
88	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.5	57
89	Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimerâ€™s Disease Pathology and Neuronal Damage. Journal of Alzheimer's Disease, 2018, 62, 385-397.	1.2	81
90	The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 130-142.	1.2	169

#	Article	IF	Citations
91	A Pilot Study of Perceived Mouth Dryness, Perceived Swallowing Effort, and Saliva Substitute Effects in Healthy Adults Across the Age Range. Dysphagia, 2018, 33, 200-205.	1.0	25
92	ICâ€Pâ€141: NEIGHBORHOOD DISADVANTAGE PREDICTS HIPPOCAMPAL VOLUME AMONG PARTICIPANTS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P118.	0.4	0
93	P1â€286: TRANSFORMATION OF CSF BIOMARKER VALUES BETWEEN MEASUREMENT BATCHES. Alzheimer's and Dementia, 2018, 14, P393.	0.4	3
94	P3â€271: LUMBAR PUNCTURE SIDE EFFECT RATES IN A RESEARCH SETTING. Alzheimer's and Dementia, 2018, 14, P1180.	0.4	3
95	O4â€07â€06: NEIGHBORHOOD DISADVANTAGE PREDICTS HIPPOCAMPAL VOLUME AMONG PARTICIPANTS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P1420.	0.4	0
96	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 124.	3.0	273
97	DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 66, 927-934.	1.2	43
98	Cardiorespiratory fitness attenuates age-associated aggregation of white matter hyperintensities in an at-risk cohort. Alzheimer's Research and Therapy, 2018, 10, 97.	3.0	17
99	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimerâ€™s Disease: The TEAM-AD VA Cooperative Study. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 177-185.	1.2	39
100	Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology, 2018, 91, e436-e443.	1.5	38
101	Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 344-349.	1.8	6
102	The Aging Imperative-Innovations in Research, Education, and Care in Geriatric Medicine. Wisconsin Medical Journal, 2018, 117, 92-93.	0.3	0
103	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
104	Positive affect predicts cerebral glucose metabolism in late middle-aged adults. Social Cognitive and Affective Neuroscience, 2017, 12, 993-1000.	1.5	2
105	BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention. Neurology, 2017, 88, 2098-2106.	1.5	52
106	Dementia Trends in the United States. JAMA Internal Medicine, 2017, 177, 58.	2.6	5
107	Family history and TOMM40 '523 interactive associations with memory in middleâ€aged and Alzheimer's disease cohorts. Alzheimer's and Dementia, 2017, 13, 1217-1225.	0.4	12
108	Moderate Physical Activity is Associated with Cerebral Glucose Metabolism in Adults at Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1089-1097.	1.2	38

#	Article	IF	Citations
109	Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. Neurology, 2017, 88, 1650-1658.	1.5	35
110	Relationships between cardiorespiratory fitness, hippocampal volume, and episodic memory in a population at risk for Alzheimer's disease. Brain and Behavior, 2017, 7, e00625.	1.0	49
111	Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 48-55.	1.2	31
112	Gut microbiome alterations in Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13537.	1.6	1,256
113	[O2â€“05â€“06]: GUT MICROBIOME ALTERATIONS IN ALZHEIMER'S DISEASE AND THE RELATIONSHIP WITH CSF BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P563.	0.4	3
114	Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology, 2017, 89, 1782-1788.	1.5	76
115	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
116	Cognitive Variability Predicts Incident Alzheimerâ€™s Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker. Journal of Alzheimer's Disease, 2017, 61, 79-89.	1.2	30
117	[ICâ€Pâ€066]: AD FAMILY HISTORY MODULATES EFFECTS OF TOMM40 â€˜523â€™ POLYâ€T ON MTL ATROPHY AND HYPOMETABOLISM IN PRECLINICAL AND AD COHORTS. Alzheimer's and Dementia, 2017, 13, P54.	0.4	0
118	Longitudinal Assessment of Self- and Informant-Subjective Cognitive Complaints in a Sample of Healthy Late-Middle Aged Adults Enriched with a Family History of Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2017, 23, 617-626.	1.2	17
119	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology, 2017, 89, 445-453.	1.5	166
120	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurology, 2017, 74, 41.	4.5	147
121	Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2249-2261.	2.4	46
122	[P3â€“331]: 4Dâ€FLOW IN THE CEREBRAL ARTERIES PROVIDES UNIQUE INFORMATION ABOUT CEREBROVASCULAR HEALTH BEYOND ISCHEMIC LESION BURDEN AND SIGNIFICANTLY PREDICTS COGNITIVE OUTCOMES. Alzheimer's and Dementia, 2017, 13, P1078.	0.4	0
123	[P3â€“423]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P1128.	0.4	0
124	[P4â€“163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS. Alzheimer's and Dementia, 2017, 13, P1322.	0.4	0
125	[P4â€“301]: COMPARING COGNITIVE BATTERIES: UNIFORM DATA SET 2 (UDSâ€2) AND UNIFORM DATA SET 3 (UDSâ€3) IN NONâ€HISPANIC WHITE PARTICIPANTS AND THOSE FROM UNDERREPRESENTED GROUPS ENROLLED IN THE WISCONSIN ALZHEIMER'S DISEASE RESEARCH CENTER'S CLINICAL CORE. Alzheimer's and Dementia, 2017, 13, P1405.	0.4	0
126	[ICâ€Pâ€049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0

#	Article	IF	Citations
127	[ICâ€Pâ€156]: 4Dâ€FLOW IN THE CEREBRAL ARTERIES PROVIDES UNIQUE INFORMATION ABOUT CEREBROVASCULAR HEALTH BEYOND ISCHEMIC LESION BURDEN AND SIGNIFICANTLY PREDICTS COGNITIVE OUTCOMES. Alzheimer's and Dementia, 2017, 13, P117.	0.4	0
128	[P1â€“503]: MODIFIABLE RISK FACTORS MODERATE THE RELATIONSHIP BETWEEN BETAâ€AMYLOID AND LONGITUDINAL COGNITIVE TRAJECTORIES IN THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION STUDY. Alzheimer's and Dementia, 2017, 13, P485.	0.4	0
129	[P1â€“526]: THE WRAPâ€AROUND APPROACH: A NOVEL RENTENTION STRATEGY IN THE AAâ€FAIM STUDY. Alzheimer's and Dementia, 2017, 13, P495.	0.4	0
130	[P1â€“611]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE É›4+ ADULTS. Alzheimer's and Dementia, 2017, 13, P530.	0.4	0
131	[P2â€“123]: ASSOCIATION OF CHOLESTEROL AND CHOLESTEROL METABOLISM GENES WITH COGNITIVE FUNCTION IN A POPULATION ENRICHED FOR A PARENTAL HISTORY OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P654.	0.4	0
132	[P2â€“208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE. Alzheimer's and Dementia, 2017, 13, P689.	0.4	1
133	[O1â€“10â€“01]: EVIDENCE FOR EARLY DETECTION OF CSF BETAâ€AMYLOID AND TAU AND EFFECT ON LONGITUDINAL COGNITIVE PERFORMANCE IN INDIVIDUALS AT RISK FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P213.	0.4	0
134	[O3â€“10â€“02]: LONGITUDINAL CSF BIOMARKER CHANGES IN MIDDLEâ€AGED ADULTS AT RISK FOR AD: THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION (WRAP) AND WISCONSIN ADRC COHORTS. Alzheimer's and Dementia, 2017, 13, P923.	0.4	1
135	[O3â€“11â€“03]: MODERATE INTENSITY PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P927.	0.4	0
136	[O5â€“01â€“05]: COHORT AND RACE DIFFERENCES IN FACTORS ASSOCIATED WITH ATTRITION IN LONGITUDINAL STUDIES OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1454.	0.4	1
137	[ICâ€Pâ€171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P128.	0.4	0
138	[P4â€“286]: A COMPARISON OF METHODS TO MEASURE INTRAâ€INDIVIDUAL COGNITIVE VARIABILITY IN NONâ€HISPANIC WHITES AND AFRICAN AMERICANS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP). Alzheimer's and Dementia, 2017, 13, P1394.	0.4	0
139	Chronotropic Response and Cognitive Function in a Cohort at Risk forÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 351-359.	1.2	1
140	Microstructural white matter alterations in preclinical Alzheimerâ€™s disease detected using free water elimination diffusion tensor imaging. PLoS ONE, 2017, 12, e0173982.	1.1	104
141	Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. Journal of Alzheimer's Disease, 2017, 60, 243-252.	1.2	15
142	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	1.2	51
143	Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 657-665.	5.5	49
144	Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-Î² Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 473-484.	1.2	93

#	Article	IF	Citations
145	Associations between Performance onÂanÂAbbreviated CogState Battery, OtherÂMeasures of Cognitive Function, andÂBiomarkers in People at Risk forÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 1395-1408.	1.2	40
146	O1â€12â€05: Amyloid Deposition in the Posterior Cingulate is Associated with Altered Microstructure in Cognitively Asymptomatic Individuals: Findings From the Wrap Study. Alzheimer's and Dementia, 2016, 12, P207.	0.4	0
147	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe Î•4 Carriers. , 2016, 12, P375-P376.		0
148	ICâ€Pâ€050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P41.	0.4	0
149	ICâ€Pâ€069: Effects of Kibra Polymorphism on White Matter Integrity: Findings from The Wisconsin Registry for Alzheimerâ€™s Prevention. Alzheimer's and Dementia, 2016, 12, P54.	0.4	0
150	IC-P-071: Longevity Gene Klotho Alters Apoe4-Related Cortical Thinning: Findings from The Wisconsin Registry for Alzheimerâ€™s Prevention. , 2016, 12, P56-P56.		0
151	P1-274: Patterns of In-Vivo Preclinical TAU and Amyloid Burden Using [F-18]THK5351 and [C-11]PIB. , 2016, 12, P521-P522.		0
152	P1â€322: Fourâ€Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI. Alzheimer's and Dementia, 2016, 12, P548.	0.4	0
153	P1â€344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P561.	0.4	0
154	P1â€410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults. Alzheimer's and Dementia, 2016, 12, P591.	0.4	0
155	ICâ€Pâ€123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI. Alzheimer's and Dementia, 2016, 12, P91.	0.4	0
156	P3â€084: Effects of Kibra Polymorphism on White Matter Integrity: Findings from the Wisconsin Registry for Alzheimerâ€™s Prevention. Alzheimer's and Dementia, 2016, 12, P850.	0.4	0
157	IC-P-178: Occupational Complexity, Cognitive Reserve, and White Matter Hyperintensities: Findings from The Wisconsin Registry for Alzheimer's Prevention. , 2016, 12, P130-P130.		3
158	ICâ€Pâ€195: Patterns of inâ€Vivo Preclinical TAU and Amyloid Burden Using [Fâ€18]THK5351 and [Câ€11]PIB. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
159	O3-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER's PREVENTION. , 2016, 12, P285-P286.		0
160	O3â€05â€01: Occupational Complexity, Cognitive Reserve, and White Matter Hyperintensities: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P294.	0.4	0
161	O3â€09â€01: Distinct Cognitive Trajectories in Late Middleâ€Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P306.	0.4	0
162	O5â€01â€05: Longevity Gene KLOTHO Alters APOE4â€Related Cortical Thinning: Findings from the Wisconsin Registry for Alzheimerâ€™s Prevention. Alzheimer's and Dementia, 2016, 12, P377.	0.4	0

#	Article	IF	Citations
163	P4â€335: Postmortem Cerebrovascular Disease and White Matter Pallor are Associated with Lower Antemortem Cerebral Perfusion, Increased White Matter Hyperintensities, and Poor Learning. Alzheimer's and Dementia, 2016, 12, P1162.	0.4	0
164	Cerebrospinal Fluid Markers of Alzheimerâ€™s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 873-886.	1.2	101
165	Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 14-17.	1.2	27
166	Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. Archives of Clinical Neuropsychology, 2016, 31, 675-688.	0.3	48
167	Age-dependent differences in brain tissue microstructure assessed with neurite orientation dispersion and density imaging. Neurobiology of Aging, 2016, 43, 79-88.	1.5	61
168	Cognitive variabilityâ€"A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 47-55.	1.2	22
169	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. Alzheimer's and Dementia, 2016, 12, 1186-1196.	0.4	180
170	Measuring informed consent capacity in an Alzheimer's disease clinical trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 258-266.	1.8	11
171	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
172	Labelâ€free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. Proteomics - Clinical Applications, 2016, 10, 1225-1241.	0.8	30
173	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain, 2016, 139, 2261-2274.	3.7	41
174	Cerebrospinal fluid ratios with AÎ²₄₂ predict preclinical brain Î²â€amyloid accumulation. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 27-38.	1.2	44
175	Betaâ€amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimer's and Dementia, 2016, 12, 805-814.	0.4	59
176	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. Journal of the International Neuropsychological Society, 2015, 21, 841-850.	1.2	49
177	P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P766-P766.		1
178	Intracranial arterial fourâ€dimensional flow is associated with metrics ofÂbrain health and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 420-428.	1.2	28
179	IC-P-063: Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P47-P49.		1
180	P3-103: Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer's disease: Findings from the wisconsin adrc impact cohort. , 2015, 11, P659-P660.		0

#	Article	IF	Citations
181	IC-P-096: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy APOE4 carriers. , 2015, 11, P66-P67.		0
182	IC-P-128: Alterations in myelin content are related to cognitive performance in nondemented older adults: Findings from the wisconsin registry for Alzheimer's prevention study. , 2015, 11, P87-P87.		1
183	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE Îµ4 carriers. , 2015, 11, P427-P428.		0
184	P4-264: Amyloid pathology is associated with extensive myelin alteration in preclinical Alzheimer's disease: New insights into disease process with novel brain imaging. , 2015, 11, P885-P885.		0
185	O1â€01â€03: Alzheimer's disease biomarkerâ€based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry for Alzheimer's prevention (WRAP). Alzheimer's and Dementia, 2015, 11, P123.	0.4	2
186	Cognitive Effects of Soy Isoflavones in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 1009-1019.	1.2	74
187	P2-210: Subjective memory complaints in middle-aged adults with a family history of Alzheimer's disease. , 2015, 11, P573-P574.		0
188	P1-199: ApoE-e4 is associated with altered myelin content in preclinical ad. , 2015, 11, P425-P425.		1
189	IC-P-015: High amyloid load is associated with episodic memory decline and incident mild cognitive impairment in middle-aged adults in the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P21-P21.		0
190	IC-03-01: Cardiorespiratory capacity correlates with cerebral blood flow, white matter hyperintensities, and cognition in preclinical Alzheimer's disease. , 2015, 11, P8-P8.		0
191	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE É›4 Carriers. Journal of Alzheimer's Disease, 2015, 46, 525-533.	1.2	65
192	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPSâ€“Cognitive and Affective Study. PLoS Medicine, 2015, 12, e1001833.	3.9	330
193	Subjective memory complaints, cortical thinning, and cognitive dysfunction in middleâ€age adults at risk of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 33-40.	1.2	90
194	P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P793-P794.		0
195	IC-P-044: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P37-P38.		0
196	P3-156: Elevated cardiovascular risk is associated with altered myelin content. , 2015, 11, P688-P688.		0
197	P1-023: Cardiorespiratory capacity correlates with cerebral blood flow, white matter hyperintensities, and cognition in preclinical Alzheimer's disease. , 2015, 11, P345-P345.		0
198	O1-07-03: High amyloid load is associated with episodic memory decline and incident mild cognitive impairment in middle-aged adults in the wisconsin registry for Alzheimer's prevention (WRAP). , 2015, 11, P142-P143.		0

#	Article	IF	Citations
199	Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimerâ€™s disease. Brain Imaging and Behavior, 2015, 9, 639-649.	1.1	85
200	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middleâ€“Aged Adults at Risk for Alzheimer Disease. JAMA Neurology, 2015, 72, 1013.	4.5	305
201	Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiology of Aging, 2015, 36, 2568-2576.	1.5	183
202	Posteromedial hyperactivation during episodic recognition among people with memory decline: findings from the WRAP study. Brain Imaging and Behavior, 2015, 9, 690-702.	1.1	3
203	Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimerâ€™s disease. Brain Imaging and Behavior, 2015, 9, 729-736.	1.1	48
204	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. JAMA Neurology, 2015, 72, 699.	4.5	75
205	Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 160-169.	1.2	34
206	Occupational Complexity and Cognitive Reserve in a Middle-Aged Cohort at Risk for Alzheimer's Disease. Archives of Clinical Neuropsychology, 2015, 30, 634-642.	0.3	96
207	Insulin resistance predicts brain amyloid deposition in late middleâ€aged adults. Alzheimer's and Dementia, 2015, 11, 504.	0.4	196
208	The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. Journal of Alzheimer's Disease, 2014, 40, 331-341.	1.2	25
209	Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology, 2014, 83, 1753-1760.	1.5	181
210	Amyloid Burden, Neuronal Function, and Cognitive Decline in Middle-Aged Adults at Risk for Alzheimer's Disease. Journal of the International Neuropsychological Society, 2014, 20, 422-433.	1.2	23
211	Cerebral Blood Flow is Diminished in Asymptomatic Middle-Aged Adults with Maternal History of Alzheimer's Disease. Cerebral Cortex, 2014, 24, 978-988.	1.6	85
212	Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data. Alzheimer's and Dementia, 2014, 10, 36-44.	0.4	46
213	Effects of hormone therapy on cognition and mood. Fertility and Sterility, 2014, 101, 898-904.	0.5	62
214	Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease. JAMA - Journal of the American Medical Association, 2014, 311, 33.	3.8	488
215	Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiology of Aging, 2014, 35, 576-584.	1.5	166
216	Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation. NeuroImage: Clinical, 2014, 4, 604-614.	1.4	119

#	Article	IF	Citations
217	Cerebrospinal fluid sphingolipids, Î²-amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2486-2494.	1.5	57
218	P1-229: THE RELATIONSHIP BETWEEN CEREBRAL PERFUSION, AGE, AND APOE4 IN MIDDLE-AGED ADULTS AT RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P388-P388.		0
219	IC-P-102: THE RELATIONSHIP BETWEEN CEREBRAL PERFUSION, AGE, AND APOE4 IN MIDDLE-AGED ADULTS AT RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P57-P58.		0
220	IC-P-007: PATTERNS OF [C-11]PIB AMYLOID BURDEN THAT ARE ASSOCIATED WITH CEREBROSPINAL FLUID AD BIOMARKERS IN PEOPLE AT RISK FOR ALZHEIMER'S DISEASE: FINDINGS FROM THE WRAP STUDY. , 2014, 10, P10-P10.		0
221	Low cerebral blood flow is associated with lower memory function in metabolic syndrome. Obesity, 2013, 21, 1313-1320.	1.5	117
222	Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Research, 2013, 1514, 12-17.	1.1	62
223	Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middleâ€"Aged Adults. Diabetes Care, 2013, 36, 443-449.	4.3	173
224	Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance. PLoS ONE, 2013, 8, e68741.	1.1	16
225	Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimerâ€™s Disease: A Pilot Study. Current Alzheimer Research, 2012, 9, 990-997.	0.7	27
226	Using predictors of hormone therapy use to model the healthy user bias. Menopause, 2012, 19, 524-533.	0.8	14
227	Cognitive response to estradiol in postmenopausal women is modified by high cortisol. Neurobiology of Aging, 2012, 33, 829.e9-829.e20.	1.5	17
228	CSF T-Tau/AÎ²42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e37720.	1.1	84
229	The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial. Journal of Alzheimer's Disease, 2012, 32, 147-156.	1.2	58
230	Medial prefrontal functional connectivityâ€"Relation to memory self-appraisal accuracy in older adults with and without memory disorders. Neuropsychologia, 2012, 50, 603-611.	0.7	46
231	Neurobiological Underpinnings of the Estrogen - Mood Relationship. Current Psychiatry Reviews, 2012, 8, 247-256.	0.9	117
232	The effect of TOMM40 polyâ€T length on gray matter volume and cognition in middleâ€aged persons with APOEÉ3/É3 genotype. Alzheimer's and Dementia, 2011, 7, 456-465.	0.4	103
233	Short-term Hormone Therapy with Transdermal Estradiol Improves Cognition for Postmenopausal Women with Alzheimer's Disease: Results of a Randomized Controlled Trial. Journal of Alzheimer's Disease, 2011, 26, 495-505.	1.2	80
234	Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults. Frontiers in Aging Neuroscience, 2010, 2, .	1.7	47

#	Article	IF	Citations
235	NSAIDs may protect against age-related brain atrophy. Frontiers in Aging Neuroscience, 2010, 2, .	1.7	14
236	Awareness of Memory Abilities in Community-Dwelling Older Adults with Suspected Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2010, 30, 83-92.	0.7	28
237	White matter is altered with parental family history of Alzheimer's disease. Alzheimer's and Dementia, 2010, 6, 394-403.	0.4	109
238	Frontiers proposal. National Institute on Aging â€œbench to bedside: estrogen as a case studyâ€. Age, 2009, 31, 199-210.	3.0	25
239	Cognitive benefits of hormone therapy: Cardiovascular factors and healthy-user bias. Maturitas, 2009, 64, 182-187.	1.0	13
240	Effects of Insulin and Octreotide on Memory and Growth Hormone in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 595-602.	1.2	21
241	Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. American Journal of Translational Research (discontinued), 2009, 1, 131-47.	0.0	12
242	Atorvastatin Therapy is Associated with Greater and Faster Cerebral Hemodynamic Response. Brain Imaging and Behavior, 2008, 2, 94-104.	1.1	5
243	Magnetic Resonance Imaging Characterization of Brain Structure and Function in Mild Cognitive Impairment: A Review. Journal of the American Geriatrics Society, 2008, 56, 920-934.	1.3	130
244	fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: Risk factors for Alzheimer's disease. Neuropsychologia, 2008, 46, 1667-1678.	0.7	58
245	Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimer's and Dementia, 2008, 4, 285-290.	0.4	88
246	Associative Learning Over Trials Activates the Hippocampus in Healthy Elderly but not Mild Cognitive Impairment. Aging, Neuropsychology, and Cognition, 2008, 15, 129-145.	0.7	33
247	A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age and Ageing, 2008, 38, 86-93.	0.7	82
248	The influence of parental history of Alzheimer's disease and apolipoprotein E Â4 on the BOLD signal during recognition memory. Brain, 2008, 132, 383-391.	3.7	79
249	Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 187-197.	1.2	88
250	Effect of Alzheimer Disease Risk on Brain Function During Self-appraisal in Healthy Middle-aged Adults. Archives of General Psychiatry, 2007, 64, 1163.	13.8	35
251	Anosognosia in mild cognitive impairment: Relationship to activation of cortical midline structures involved in self-appraisal. Journal of the International Neuropsychological Society, 2007, 13, 450-61.	1.2	109
252	Structural MRI discriminates individuals with Mild Cognitive Impairment from age-matched controls: A combined neuropsychological and voxel based morphometry study. , 2006, 2, ALZJJALZ200606001.		39

#	Article	IF	Citations
253	Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 38-41.	1.5	73
254	Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's Disease: a cross-sectional study. BMC Medicine, 2006, 4, 1.	2.3	152
255	The Influence of Alzheimer Disease Family History and Apolipoprotein E Â4 on Mesial Temporal Lobe Activation. Journal of Neuroscience, 2006, 26, 6069-6076.	1.7	152
256	Estrogen, Cognition, and Dementia. Annals of the New York Academy of Sciences, 2005, 1055, 228-228.	1.8	1
257	Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations. Annals of the New York Academy of Sciences, 2005, 1052, 93-115.	1.8	51
258	Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone. American Journal of Geriatric Psychiatry, 2005, 13, 950-958.	0.6	62
259	Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone: A Preliminary Study. American Journal of Geriatric Psychiatry, 2005, 13, 950-958.	0.6	498
260	Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, M461-M465.	1.7	32
261	Estrogen and Cognition: A True Relationship?. Journal of the American Geriatrics Society, 2004, 52, 316-318.	1.3	13
262	Insulin doseâ€"response effects on memory and plasma amyloid precursor protein in Alzheimerâ€™s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology, 2003, 28, 809-822.	1.3	233
263	17Î²-Estradiol Reduces Plasma AÎ²40 for HRT-NaÃ¯ve Postmenopausal Women With Alzheimer Disease: A Preliminary Study. American Journal of Geriatric Psychiatry, 2003, 11, 239-244.	0.6	2
264	Estrogen and Cognition: The Story So Far. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M322-M323.	1.7	17
265	17beta-estradiol reduces plasma Abeta40 for HRT-naÃ¯ve postmenopausal women with Alzheimer disease: a preliminary study. American Journal of Geriatric Psychiatry, 2003, 11, 239-44.	0.6	25
266	Estrogen and Alzheimer??s Disease. Drugs and Aging, 2002, 19, 405-427.	1.3	92
267	Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein-E Genotype. Annals of the New York Academy of Sciences, 2000, 903, 222-228.	1.8	175
268	Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose. Archives of General Psychiatry, 1999, 56, 1135.	13.8	287
269	Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimerâ€™s disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology, 1999, 24, 657-678.	1.3	225
270	Insulin Metabolism in Alzheimerâ€™s Disease Differs According to Apolipoprotein E Genotype and Gender. Neuroendocrinology, 1999, 70, 146-152.	1.2	147

#	Article	IF	Citations
271	Potential Role of Muscarinic Agonists in AlzheimerÊ¼s Disease. Drugs and Aging, 1997, 11, 450-459.	1.3	57
272	Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease*. Clinical Pharmacology and Therapeutics, 1996, 60, 276-282.	2.3	51
273	Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease*. Clinical Pharmacology and Therapeutics, 1995, 58, 299-309.	2.3	58
274	Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease. Psychoneuroendocrinology, 1995, 20, 623-636.	1.3	19
275	Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology, 1993, 112, 421-427.	1.5	68
276	Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the alzheimer type. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1991, 15, 643-648.	2.5	20
277	The use of transdermal 17Î²-estradiol in the treatment of Alzheimer's disease. , 0, , 80-86.		0